BioSpace News Archive

Merus N.V. announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® Annual Meeting taking place in Chicago May 31-June 4, 2024.

CatalYm announced positive new follow-up results from its ongoing “GDFATHER” Phase 1/2a trial in an oral presentation at the American Society of Clinical Oncology Annual Meeting 2024 in Chicago.

Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations, after chemoradiotherapy compared to placebo after CRT.

Genmab A/S announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma.

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.

Telix Pharmaceuticals Limited announces that it has completed the submission of a Biologics License Application to the United States Food and Drug Administration for its investigational radiodiagnostic PET1 agent, TLX250-CDx, for the characterisation of renal masses as clear cell renal cell carcinoma.

HUTCHMED Limited announces that results from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were published in Nature Medicine.

Mesoblast Limited, Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.

Immutep Limited announced that it has entered into a clinical trial collaboration and supply agreement with MSD, through a subsidiary, to evaluate eftilagimod alfa in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in a pivotal Phase III trial.

Keymed Biosciences Inc. announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis has been released by way of oral presentation at the European Academy of Allergy and Clinical Immunology Congress 2024.